SciClone Pharmaceuticals, Inc.

270 articles with SciClone Pharmaceuticals, Inc.

• SciClone Pharmaceuticals, Inc. To Report Financial Results For The First Quarter 2014 On May 12th

  5/5/2014

• SciClone Pharmaceuticals, Inc. Selects rfXcel To Meet China Product Compliance And Anti-Counterfeiting Goal

  4/23/2014

• SciClone Pharmaceuticals, Inc. To Present At Needham Healthcare Conference On April 8, 2014

  4/2/2014

• SciClone Pharmaceuticals, Inc. Reports 2013 Financial Results And 2014 Outlook

  3/12/2014

• SciClone Pharmaceuticals, Inc. To Report Financial Results For The Fourth Quarter And Full Year 2013 On March 12th

  3/5/2014

• SciClone Pharmaceuticals, Inc. Appoints Charles Meng As General Counsel And Vice President Of Compliance

  2/10/2014

• SciClone Pharmaceuticals, Inc. To Present At Biotechnology Industry Organization (BIO) CEO & Investor Conference On February 11, 2014

  2/4/2014

• SciClone Pharmaceuticals, Inc. Announces Transition From Pricewaterhousecoopers LLP To Pricewaterhousecoopers Zhong Tian LLP As Independent Registered Public Accounting Firm

  1/27/2014

• SciClone Pharmaceuticals, Inc. Provides 2013 Financial Update And 2014 Guidance

  1/9/2014

• SciClone Pharmaceuticals, Inc. To Present At Oppenheimer Healthcare Conference On December 10, 2013

  12/2/2013

• SciClone Pharmaceuticals, Inc. Reports Financial Results For The Three And Nine Months Ended September 30, 2013

  11/12/2013

• SciClone Pharmaceuticals, Inc. Appoints Nancy T. Chang, Ph.D., to Its Board of Directors

  9/23/2013

• SciClone Pharmaceuticals, Inc. Gets New Subpoena From SEC in FCPA Probe

  8/13/2013

• SciClone Pharmaceuticals, Inc. Reports Financial Results for the Three and Six Months Ended June 30, 2013 and Updates 2013 Guidance

  8/7/2013

• SciClone Pharmaceuticals, Inc. Appoints Wilson W. Cheung as Chief Financial Officer

  7/15/2013

• Soligenix Announces Commercial Collaboration With SciClone Pharmaceuticals, Inc. in China for SGX942 in the Treatment of Oral Mucositis

  7/8/2013

• SciClone Pharmaceuticals, Inc. and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow®, a Novel Treatment for Peripheral Arterial Disease for the China Market

  6/25/2013

• SciClone Pharmaceuticals, Inc. Reports Anticipated Financial Results for the First Quarter 2013

  5/17/2013

• SciClone Pharmaceuticals, Inc. Reaches Neucardin Deal for Up to $40.5 Million With Zensun

  5/17/2013

• SciClone Pharmaceuticals, Inc. Appoints PricewaterhouseCoopers LLP as Its Independent Registered Public Accounting Firm

  4/8/2013